Biomarin Pharmaceutical: Peers

The FY2025 (Dec) proxy of Biomarin Pharmaceutical names 14 peer companies for pay. Among Biomarin Pharmaceutical and these peers, CEO pay was 4th highest of 9 and total shareholder return was the lowest of 9.

4th highest of 9in Biomarin Pharmaceutical and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

9th highest of 9in Biomarin Pharmaceutical and its pay peers, FY2025 (Dec) by total shareholder return:

$68$321

Pay peer group, FY2025 (Dec) proxy

Exelixis
Incyte
Gilead Sciences
United Therapeutics
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Regeneron Pharmaceuticals
Neurocrine Biosciences
BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.)Not disclosedNot disclosed
BiogenNot disclosedNot disclosed
Jazz PharmaceuticalsNot disclosedNot disclosed
Sarepta Therapeutics, Inc.Not disclosedNot disclosed
Ultragenyx Pharmaceuticals Inc.Not disclosedNot disclosed
Vertex Pharmaceuticals IncorporatedNot disclosedNot disclosed
14 companies

Changes by year

FY2025 (Dec) proxy

  • AddedGilead Sciencespay peer groupThe 2025 Peer Group reflects a slight change from the 2024 peer group by (i) removing Horizon Therapeutics plc and Seagen Inc., both of which were acquired and no longer public, and (ii) adding Gilead Sciences, Inc., Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc. based on the review process and criteria discussed above
  • AddedSarepta Therapeutics, Inc.pay peer groupThe 2025 Peer Group reflects a slight change from the 2024 peer group by (i) removing Horizon Therapeutics plc and Seagen Inc., both of which were acquired and no longer public, and (ii) adding Gilead Sciences, Inc., Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc. based on the review process and criteria discussed above
  • AddedUltragenyx Pharmaceuticals, Inc.pay peer groupThe 2025 Peer Group reflects a slight change from the 2024 peer group by (i) removing Horizon Therapeutics plc and Seagen Inc., both of which were acquired and no longer public, and (ii) adding Gilead Sciences, Inc., Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc. based on the review process and criteria discussed above
  • RemovedHorizon Therapeutics plcpay peer groupThe 2025 Peer Group reflects a slight change from the 2024 peer group by (i) removing Horizon Therapeutics plc and Seagen Inc., both of which were acquired and no longer public, and (ii) adding Gilead Sciences, Inc., Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc. based on the review process and criteria discussed above
  • RemovedSeagen Inc.pay peer groupThe 2025 Peer Group reflects a slight change from the 2024 peer group by (i) removing Horizon Therapeutics plc and Seagen Inc., both of which were acquired and no longer public, and (ii) adding Gilead Sciences, Inc., Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceuticals, Inc. based on the review process and criteria discussed above

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.